2024
Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study.
Peng C, Saffo S, Oberstein P, Shusterman M, Thomas C, Becker D, Berlin J, Leichman L, Boursi B, Nagar A, Yu S. Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study. Journal Of The National Comprehensive Cancer Network 2024, 22: 521-527. PMID: 39236754, DOI: 10.6004/jnccn.2024.7029.Peer-Reviewed Original ResearchMultidrug regimensFOLFIRINOX regimensAdvanced colorectalGastrointestinal cancerAssociated with decreased survivalGranulocyte colony-stimulating factorCompare survival outcomesGastrointestinal cancer treatmentBaseline clinical factorsKaplan-Meier analysisFirst-line FOLFOXMulticenter cohort studyColony-stimulating factorInverse probability of treatmentAdvanced gastrointestinal cancerTreatment selection biasProbability of treatmentHealth care savingsCox proportional hazardsOverall survivalEffective regimenIPTW analysisSurvival outcomesPancreatic cancerAssociated with reductions
2023
Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer.
Peng C, Saffo S, Shusterman M, Becker D, Berlin J, Oberstein P, Nagar A, Yu S. Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer. Journal Of Clinical Oncology 2023, 41: 59-59. DOI: 10.1200/jco.2023.41.4_suppl.59.Peer-Reviewed Original ResearchMetastatic colorectal cancerOverall survivalECOG scoreColorectal cancerUnivariable Cox proportional hazards modelsFirst-line treatment regimensCox proportional hazards modelHigh-risk comorbiditiesHigher ECOG scoreRole of bolusMulticenter cohort studyOverall survival benefitRisk of deathLimited functional statusCombination drug regimenProportional hazards modelUse of bolusPropensity-score matchingAdjuvant settingBaseline creatinineFlatiron HealthMedian followCohort studyCreatinine levelsDrug regimen